BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433. [PMID: 12019668 DOI: 10.4088/jcp.v63n0509] [Cited by in Crossref: 174] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Song X, Li X, Gao J, Zhao J, Li Y, Fan X, Lv L. APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia. PLoS One 2014;9:e93902. [PMID: 24710015 DOI: 10.1371/journal.pone.0093902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
2 Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011;25:1035-59. [PMID: 22133326 DOI: 10.2165/11596300-000000000-00000] [Cited by in Crossref: 100] [Cited by in F6Publishing: 71] [Article Influence: 11.1] [Reference Citation Analysis]
3 Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain : a literature analysis. Drug Saf 2006;29:303-19. [PMID: 16569080 DOI: 10.2165/00002018-200629040-00002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
4 Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009;66:838-47. [PMID: 19652123 DOI: 10.1001/archgenpsychiatry.2009.79] [Cited by in Crossref: 97] [Cited by in F6Publishing: 62] [Article Influence: 8.1] [Reference Citation Analysis]
5 Dehelean L, Romosan AM, Manea MM, Papava I, Andor M, Romosan RS. THE METABOLIC SYNDROME IN OUTPATIENTS WITH PSYCHOSIS: A COMPARATIVE STUDY BETWEEN LONG ACTING INJECTABLE OLANZAPINE AND RISPERIDONE. Acta Endocrinol (Buchar) 2019;15:342-8. [PMID: 32010353 DOI: 10.4183/aeb.2019.342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Jin H, Meyer JM, Mudaliar S, Jeste DV. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008;100:70-85. [PMID: 18206351 DOI: 10.1016/j.schres.2007.11.026] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
7 Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav 2011;104:590-8. [PMID: 21664918 DOI: 10.1016/j.physbeh.2011.05.033] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
8 Irwin N, Gault VA. Unraveling the mechanisms underlying olanzapine-induced insulin resistance. Diabetes 2013;62:3022-3. [PMID: 23970523 DOI: 10.2337/db13-0804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Holtzheimer PE 3rd, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006;3:42-56. [PMID: 16490412 DOI: 10.1016/j.nurx.2005.12.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
10 Brooks JO 3rd, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep 2009;11:33-40. [PMID: 19187706 DOI: 10.1007/s11920-009-0006-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
11 Rakofsky JJ, Holtzheimer PE, Nemeroff CB. Emerging targets for antidepressant therapies. Curr Opin Chem Biol 2009;13:291-302. [PMID: 19501541 DOI: 10.1016/j.cbpa.2009.04.617] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
12 Grover S, Malhotra N, Chakrabarti S, Kulhara P. Metabolic syndrome in bipolar disorders. Indian J Psychol Med 2012;34:110-8. [PMID: 23162184 DOI: 10.4103/0253-7176.101767] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
13 Irvin MR, Wiener HW, Perry RP, Savage RM, Go RC. Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;114:50-6. [PMID: 19643578 DOI: 10.1016/j.schres.2009.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
14 Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat 2019;15:2087-99. [PMID: 31413575 DOI: 10.2147/NDT.S208061] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
15 Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005;65:1113-38. [PMID: 15907146 DOI: 10.2165/00003495-200565080-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
16 Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33. [PMID: 20692814 DOI: 10.1016/j.schres.2010.07.012] [Cited by in Crossref: 395] [Cited by in F6Publishing: 301] [Article Influence: 35.9] [Reference Citation Analysis]
17 Sahoo S, Mishra B, Akhtar S. Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report. Br J Clin Pharmacol 2007;64:715-6. [PMID: 17509037 DOI: 10.1111/j.1365-2125.2007.02941.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19 Suppl 1:1-93. [PMID: 15998156 DOI: 10.2165/00023210-200519001-00001] [Cited by in Crossref: 366] [Cited by in F6Publishing: 452] [Article Influence: 22.9] [Reference Citation Analysis]
19 Mossaheb N, Wiesegger G, Amminger GP, Kasper S, Tauscher J. [Early recognition and intervention for schizophrenia]. Nervenarzt 2006;77:23-4, 27-30, 32-4. [PMID: 15931537 DOI: 10.1007/s00115-005-1925-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
20 Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003;74:277-90. [PMID: 12918602 DOI: 10.1023/a:1024170622266] [Cited by in Crossref: 30] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
21 Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP. Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Prim Care Companion J Clin Psychiatry 2003;5:6-14. [PMID: 15156241 DOI: 10.4088/pcc.v05n0103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ; ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173-196. [PMID: 21445724 DOI: 10.1007/s00787-011-0163-7] [Cited by in Crossref: 278] [Cited by in F6Publishing: 172] [Article Influence: 27.8] [Reference Citation Analysis]
23 Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol. 2014;5:405-415. [PMID: 25400984 DOI: 10.4291/wjgp.v5.i4.405] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 28] [Article Influence: 7.1] [Reference Citation Analysis]
24 McKibbin CL, Golshan S, Griver K, Kitchen K, Wykes TL. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis. Schizophr Res 2010;121:203-6. [PMID: 20434886 DOI: 10.1016/j.schres.2009.09.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
25 Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008;7:58-62. [PMID: 18458771 DOI: 10.1002/j.2051-5545.2008.tb00154.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
26 Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004;19:1200-5. [PMID: 15610330 DOI: 10.1111/j.1525-1497.2004.40126.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
27 Haddad C, Hallit S, Salameh P, Bou-Assi T, Zoghbi M. Coronary heart disease risk in patients with schizophrenia: a Lebanese cross-sectional study. J Comorb 2017;7:79-88. [PMID: 29090191 DOI: 10.15256/joc.2017.7.107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Rodríguez-Martínez A, Quilo CG. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective. Clin Drug Investig 2013;33:867-76. [PMID: 24241935 DOI: 10.1007/s40261-013-0100-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Hugenholtz GW, Stolker JJ, Heerdink ER, Nolen WA, Leufkens HG. Short-acting parenteral antipsychotics drive choice for classical versus atypical agents. Eur J Clin Pharmacol 2003;58:757-60. [PMID: 12634982 DOI: 10.1007/s00228-002-0545-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Boyda HN, Procyshyn RM, Tse L, Hawkes E, Jin CH, Pang CC, Honer WG, Barr AM. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 2012;37:407-15. [PMID: 22640703 DOI: 10.1503/jpn.110140] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
31 Sugawara N, Yasui-Furukori N, Yamazaki M, Shimoda K, Mori T, Sugai T, Suzuki Y, Someya T. Psychiatrists' attitudes toward metabolic adverse events in patients with schizophrenia. PLoS One 2014;9:e86826. [PMID: 24466260 DOI: 10.1371/journal.pone.0086826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
32 Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-87. [PMID: 18775645 DOI: 10.1016/j.schres.2008.07.006] [Cited by in Crossref: 148] [Cited by in F6Publishing: 121] [Article Influence: 11.4] [Reference Citation Analysis]
33 Xu F, Fan W, Wang W, Tang W, Yang F, Zhang Y, Cai J, Song L, Zhang C. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial. Psychopharmacology (Berl) 2019;236:1273-9. [PMID: 30519766 DOI: 10.1007/s00213-018-5136-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
34 Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig 2015;12:242-8. [PMID: 25866526 DOI: 10.4306/pi.2015.12.2.242] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
35 Unsal C, Albayrak Y, Albayrak N, Kuloglu M, Hashimoto K. Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine. Neuropsychiatr Dis Treat 2013;9:1545-52. [PMID: 24143103 DOI: 10.2147/NDT.S52463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]